What is the best treatment of locally advanced nasopharyngeal carcinoma? an individual patient data network meta-analysis

Laureen Ribassin-Majed, Sophie Marguet, Anne W.M. Lee, Wai Tong Ng, Jun Ma, Anthony T.C. Chan, Pei Yu Huang, Guopei Zhu, Daniel T.T. Chua, Yong Chen, Hai Qiang Mai, Dora L.W. Kwong, Shie Lee Cheah, James Moon, Yuk Tung, Kwan Hwa Chi, George Fountzilas, Jean Bourhis, Jean Pierre Pignon, Pierre Blanchard

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    265 Citations (Scopus)

    Résumé

    Purpose The role of adjuvant chemotherapy (AC) or induction chemotherapy (IC) in the treatment of locally advanced nasopharyngeal carcinoma is controversial. The individual patient data from the Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma database were used to compare all available treatments. Methods All randomized trials of radiotherapy (RT) with or without chemotherapy in nonmetastatic nasopharyngeal carcinoma were considered. Overall, 20 trials and 5,144 patients were included. Treatments were grouped into seven categories: RT alone (RT), IC followed by RT (IC-RT), RT followed by AC (RTAC), IC followed by RT followed by AC (IC-RT-AC), concomitant chemoradiotherapy (CRT), IC followed by CRT (IC-CRT), and CRT followed by AC (CRT-AC). P-score was used to rank the treatments. Fixedand random-effects frequentist network meta-analysis models were applied. Results The three treatments with the highest probability of benefit on overall survival (OS) were CRT-AC, followed by CRT and IC-CRT, with respective hazard ratios (HRs [95% CIs]) compared with RT alone of 0.65 (0.56 to 0.75), 0.77 (0.64 to 0.92), and 0.81 (0.63 to 1.04). HRs (95% CIs) of CRT-AC compared with CRT for OS, progression-free survival (PFS), locoregional control, and distant control (DC) were, respectively, 0.85 (0.68 to 1.05), 0.81 (0.66 to 0.98), 0.70 (0.48 to 1.02), and 0.87 (0.61 to 1.25). IC-CRT ranked second for PFS and the best for DC. CRT never ranked first. HRs of CRT compared with IC-CRT for OS, PFS, locoregional control, and DC were, respectively, 0.95 (0.72 to 1.25), 1.13 (0.88 to 1.46), 1.05 (0.70 to 1.59), and 1.55 (0.94 to 2.56). Regimens with more chemotherapy were associated with increased risk of acute toxicity. Conclusion The addition of AC to CRT achieved the highest survival benefit and consistent improvement for all end points. The addition of IC to CRT achieved the highest effect on DC.

    langue originaleAnglais
    Pages (de - à)498-505
    Nombre de pages8
    journalJournal of Clinical Oncology
    Volume35
    Numéro de publication5
    Les DOIs
    étatPublié - 10 févr. 2017

    Contient cette citation